MENU
AEMD
Stock ticker: NASDAQ
PRICE
CHANGE
CAPITALIZATION

AEMD stock forecast, quote, news & analysis

Aethlon Medical Inc is a medical therapeutic company focused on developing the Hemopurifier (HP), a clinical-stage investigational immunotherapeutic device designed to address unmet needs in oncology, life-threatening infectious diseases, organ transplantation and other disease states in which extracellular vesicles (EVs) contribute to disease progression... Show more

Interact to see
Advertisement
A.I.Advisor
published price charts
A.I.Advisor
a Summary for AEMD with price predictions
Nov 04, 2026

AEMD's RSI Oscillator recovers from overbought zone

The 10-day RSI Oscillator for AEMD moved out of overbought territory on October 02, 2026. This could be a sign that the stock is shifting from an upward trend to a downward trend. Traders may want to look at selling the stock or buying put options. Tickeron's A.I.dvisor looked at 18 instances where the indicator moved out of the overbought zone. In 18 of the 18 cases the stock moved lower in the days that followed. This puts the odds of a move down at 90%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 22 of 27 cases where AEMD's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 81%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where AEMD declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.

AEMD broke above its upper Bollinger Band on November 03, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

The Aroon Indicator for AEMD entered a downward trend on October 28, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on October 28, 2026. You may want to consider a long position or call options on AEMD as a result. In 51 of 71 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 72%.

The Moving Average Convergence Divergence (MACD) for AEMD just turned positive on November 04, 2026. Looking at past instances where AEMD's MACD turned positive, the stock continued to rise in 31 of 37 cases over the following month. The odds of a continued upward trend are 84%.

Following a +3.11% 3-day Advance, the price is estimated to grow further. Considering data from situations where AEMD advanced for three days, in 150 of 193 cases, the price rose further within the following month. The odds of a continued upward trend are 78%.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of 44 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.786) is normal, around the industry mean (4.338). P/E Ratio (-0.392) is within average values for comparable stocks, (1.324). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (11.253). Dividend Yield (0.000) settles around the average of (0.010) among similar stocks. P/S Ratio (2.111) is also within normal values, averaging (40.124).

The Tickeron Price Growth Rating for this company is 58 (best 1 - 100 worst), indicating steady price growth. AEMD’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is 100 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. AEMD’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are Abbott Laboratories (NYSE:ABT), Medtronic plc (NYSE:MDT), Boston Scientific Corp (NYSE:BSX), Edwards Lifesciences Corp (NYSE:EW).

Industry description

The medical/nursing services includes companies that provide medical-related services such as ambulance services, dialysis centers, respiratory therapy, blood testing and rehabilitation services. DaVita Inc., Chemed Corporation and Guardant Health, Inc. are examples of companies in this industry.

Market Cap

The average market capitalization across the Medical/Nursing Services Industry is 6.12B. The market cap for tickers in the group ranges from 837 to 199.88B. ABT holds the highest valuation in this group at 199.88B. The lowest valued company is DHAI at 837.

High and low price notable news

The average weekly price growth across all stocks in the Medical/Nursing Services Industry was -7%. For the same Industry, the average monthly price growth was -9%, and the average quarterly price growth was -7%. NSPR experienced the highest price growth at 67%, while BDMD experienced the biggest fall at -57%.

Volume

The average weekly volume growth across all stocks in the Medical/Nursing Services Industry was -1%. For the same stocks of the Industry, the average monthly volume growth was 13% and the average quarterly volume growth was -2%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 49
P/E Growth Rating: 53
Price Growth Rating: 61
SMR Rating: 89
Profit Risk Rating: 93
Seasonality Score: 13 (-100 ... +100)
View a ticker or compare two or three
Interact to see
Advertisement
A.I. Advisor
published General Information

General Information

a provider of diagnostic and therapeutic device solutions for infectious disease, cancer and for other life threatening conditions

Industry MedicalNursingServices

Industry
Medical Specialties
Address
11555 Sorrento Valley Road
Phone
+1 619 941-0360
Employees
9
Web
https://www.aethlonmedical.com
AEMD's RSI Oscillator recovers from overbought zone